[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T: Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer; 2009 May 1;115(9):1867-74
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
  • BACKGROUND: : The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS).
  • METHODS: : Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS.
  • Quality-of-life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy.
  • Stable disease was noted in 3 of 12 patients (at 8 weeks, 12 weeks, and > or =77 weeks, respectively), and the median time to disease progression was 48 days.
  • Among the patients who had stable disease, 2 women had endometrioid endometrial cancer, and 1 woman had LGESS.
  • The most frequent grade 1 and 2 toxicities were anorexia, fatigue, and mood alterations observed in 50%, 50%, and 58% of patients, respectively.
  • The most common grade 3 toxicities were fatigue and dyspnea observed in 25% and 17% of patients, respectively.
  • One patient experienced grade 4 dyspnea.
  • No serious treatment-related adverse events occurred.
  • CONCLUSIONS: : Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%.
  • The authors concluded that further research into the best mode of application for mifepristone in the treatment of endometrial cancer is needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Endometrioid / drug therapy. Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Receptors, Progesterone / metabolism. Recurrence

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241422.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098258
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down


2. Ashraf-Ganjoei T, Behtash N, Shariat M, Mosavi A: Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol; 2006;4:50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases.
  • BACKGROUND: Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the USA or Europe per year.
  • The aim of this study was to evaluate the behavior of low-grade endometrial stromal sarcoma (LGESS) in relation to their clinical and pathological features and to identify possible prognostic factors.
  • Endometrial stromal sarcoma is characterized by proliferations composed of cells with Endometrial stromal cell differentiation.
  • Low-grade endometrial stromal sarcoma has an infiltrating margin and typically show extensive worm-like vessel invasion.
  • Radiotherapy as adjuvant therapy was administered to four patients (28.5%).
  • The median follow-up time was 45.6 months (range 24-84).
  • The recurrent diseases were treated with surgery, chemotherapy, and radiotherapy.
  • Clinico-pathological parameters did not significantly differ between patients with and without recurrence, but patients with no myometrial invasion and low mitotic count < or = 5/HPF showed longer disease-free survival.
  • Survival probabilities were calculated by the product limit method of Kaplan and Meier that showed, patients with no myometrial invasion and low mitotic count < or = 5/HPF have longer disease-free survival, but P value was not significant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):318-21 [15963554.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):632-6 [15581975.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):412-3; author reply 413 [15491769.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):256-9 [15385142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1366-73 [14630275.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):37-43 [12821339.001]
  • [Cites] Med Oncol. 2003;20(1):87-93 [12665689.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):256-60 [12040283.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] J Clin Pathol. 1999 Mar;52(3):198-202 [10450179.001]
  • [Cites] Am J Obstet Gynecol. 2000 May;182(5):1140-1 [10819848.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):120-3 [11006043.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):160-5 [11330943.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):243-5 [16054205.001]
  • (PMID = 16895611.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1560376
  •  go-up   go-down


3. Paillocher N, Lortholary A, Abadie-Lacourtoisie S, Morand C, Verriele V, Catala L, Descamps P: [Low-grade endometrial stromal sarcoma: contribution of hormone therapy and etoposide]. J Gynecol Obstet Biol Reprod (Paris); 2005 Feb;34(1 Pt 1):41-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-grade endometrial stromal sarcoma: contribution of hormone therapy and etoposide].
  • [Transliterated title] Sarcome du chorion cytogène de bas grade. Mise au point sur l'intérêt de l'hormonothérapie et de l'étoposide à partir de 4 cas.
  • Endometrial stromal sarcoma is a rare malignant uterine tumor.
  • We report 4 cases of low-grade endometrial stromal sarcoma, corresponding to the form with a mitotic index at less than 10 mitoses per 10 high power fields (HPF), from which we carried out a review of the literature and defined the potential interest of hormone therapy and chemotherapy by etoposide.
  • The initial treatment is mainly based open surgery, generally total hysterectomy with annexectomy.
  • There is no effective adjuvant treatment.
  • The potential of reccurences remains around 50% with a 34-month median.
  • Several therapeutic options are possible after recurrence but no standard treatment has been established.
  • Chemotherapy by oral etoposide offers easy administration, good compliance and acceptable toxicity with median 20-month remission in 3 patients before progression.
  • Hormone therapy with progestogens (hormone receptor expression of the tumor is 71% for estrogens and 95% for progesterone) is widely studied in the literature with a 46% response rate and 46% rate of disease stabilization.
  • Hormone therapy with an anti-aromatase appears to be a promising treatment according to the bibliographic references on this subject.
  • Overall, prognosis of low-grade endometrial sarcoma is relatively good with 100% survival at 5 years.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Endometrial Neoplasms / drug therapy. Etoposide / therapeutic use. Progestins / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767916.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Progestins; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 23
  •  go-up   go-down


Advertisement
4. Krauss K, Bachmann C, Hartmann JT, Siegmann K, Sotlar K, Wallwiener D, Huober J: Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. Anticancer Res; 2007 Sep-Oct;27(5B):3477-80
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole.
  • Low grade endometrial stromal sarcoma (LGESS) is a rare disease.
  • Treatment is ongoing.
  • Aromatase inhibitors represent an interesting treatment option for LGESS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Stromal Tumors / drug therapy. Endometrial Stromal Tumors / prevention & control. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Muscle Neoplasms / secondary. Psoas Muscles / pathology. Radiography, Abdominal. Recurrence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972504.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


5. Leunen M, Breugelmans M, De Sutter P, Bourgain C, Amy JJ: Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol; 2004 Dec;95(3):769-71
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
  • BACKGROUND: Low-grade endometrial stromal sarcoma is an indolent steroid responsive tumor.
  • Successful hormonal treatment, most commonly with megestrol acetate, has been reported.
  • After transvaginal trough-cut biopsy of the mass, the diagnosis of low-grade endometrial stromal sarcoma with a high expression of alpha-estrogen receptor was made.
  • The patient was treated with letrozole only with a spectacular response.
  • CONCLUSION: To the best of our knowledge, this is the first case for which letrozole was used on long-term basis as first-line hormonal treatment for a recurrent low-grade stromal sarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Aromatase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2005 Jul;98(1):173-4; author reply 174-5 [15963815.001]
  • (PMID = 15582003.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


6. Mesia AF, Demopoulos RI: Effects of leuprolide acetate on low-grade endometrial stromal sarcoma. Am J Obstet Gynecol; 2000 May;182(5):1140-1
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of leuprolide acetate on low-grade endometrial stromal sarcoma.
  • We describe a low-grade endometrial stromal sarcoma coexistent with leiomyoma and adenomyosis treated with leuprolide acetate.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Leuprolide / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Endometriosis / pathology. Female. Humans. Leiomyoma / drug therapy. Leiomyoma / pathology. Leiomyoma / surgery. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10819848.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] EFY6W0M8TG / Leuprolide
  •  go-up   go-down


7. Nakayama K, Ishikawa M, Nagai Y, Yaegashi N, Aoki Y, Miyazaki K: Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate. Int J Clin Oncol; 2010 Apr;15(2):179-83
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
  • BACKGROUND: The aim of this study was to investigate the usefulness of medroxyprogesterone acetate (MPA) therapy for patients with metastatic low-grade endometrial stromal sarcoma (LGESS).
  • METHODS: A retrospective review was performed of five patients with metastatic LGESS lesions in whom MPA therapy prolonged survival.
  • Three of the five patients received several types of chemotherapy, and all of these patients received the same MPA (200-600 mg/day) hormonal therapy.
  • The median overall survival from the time of recurrence was 41 months (range, 9-163 months).
  • CONCLUSION: The patients in this study demonstrate that MPA treatment may extend the survival of patients with LGESS that is metastatic to the lung.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1987 Jan;26(1):87-97 [3792939.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1888-93 [7116313.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1084-9 [18179547.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):458-60 [9887250.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):749-54 [12445254.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):37-43 [12821339.001]
  • [Cites] Cancer Lett. 2001 Jun 10;167(1):39-48 [11323097.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):567-71 [15297205.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):170-6 [12821359.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2798-803 [17602085.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 May;35(5):857-61 [18487930.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):769-71 [15582003.001]
  • [Cites] Gynecol Oncol. 1985 Jan;20(1):120-8 [3965374.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] Cancer. 1966 Jun;19(6):755-66 [5939046.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):384-8 [11531300.001]
  • [Cites] Obstet Gynecol. 1984 Aug;64(2):173-8 [6738952.001]
  • [Cites] Obstet Gynecol. 2008 Nov;112(5):1102-8 [18978112.001]
  • [Cites] Am J Clin Pathol. 1992 Mar;97(3):381-6 [1371902.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):243-5 [16054205.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):209-13 [12860344.001]
  • [Cites] Int J Gynecol Cancer. 2009 Feb;19(2):253-6 [19396004.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):275-8 [2807024.001]
  • [Cites] Med Oncol. 2003;20(1):87-93 [12665689.001]
  • (PMID = 20217451.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


8. Boardman CH, Webb MJ, Jefferies JA: Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer. Gynecol Oncol; 2000 Oct;79(1):120-3
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer.
  • OBJECTIVE: Low-grade endometrial stromal sarcoma is an uncommon, indolent uterine sarcoma that can arise in extrauterine locations.
  • The objective of this study was to report on a previously unpublished site of origin for a low-grade endometrial stromal sarcoma.
  • METHODS: A case of a low-grade endometrial stromal sarcoma arising in the ectocervix after goserelin hormonal therapy for breast cancer was studied.
  • RESULTS: Low-grade endometrial stromal sarcoma can arise in the ectocervix even in the absence of endometriosis.
  • CONCLUSION: Low-grade endometrial stromal sarcoma should be included in the differential diagnosis of sarcomas of the ectocervix.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology. Sarcoma, Endometrial Stromal / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Female. Goserelin / adverse effects. Goserelin / therapeutic use. Humans. Middle Aged


9. Lacroix-Triki M, Beyris L, Martel P, Marques B: Low-grade endometrial stromal sarcoma arising from sciatic nerve endometriosis. Obstet Gynecol; 2004 Nov;104(5 Pt 2):1147-9
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma arising from sciatic nerve endometriosis.
  • BACKGROUND: Endometrial stromal sarcoma arising from extrauterine endometriosis is a rare and not easily diagnosed tumor.
  • We present a case arising from sciatic nerve endometriosis in a 50-year-old woman.
  • CASE: The patient had a long history of endometriosis and presented with a left buttock mass and motor deficit.
  • She underwent total hysterectomy, bilateral salpingo-oophorectomy, and excision of pelvic endometriotic pockets, allowing the diagnosis of low-grade endometrial stromal sarcoma arising from endometriosis.
  • She received systemic chemotherapy, gonadotropin-releasing hormone agonist therapy, and palliative radiation therapy, but her disease progressed.
  • CONCLUSION: Aggressive endometriosis raises important diagnostic and therapeutic difficulties and may correspond to misdiagnosed rare malignant neoplasms, which should be treated.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Sarcoma, Endometrial Stromal / pathology. Sciatic Nerve / pathology
  • [MeSH-minor] Biopsy, Needle. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Laparotomy. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516431.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kalender ME, Sevinc A, Yilmaz M, Ozsarac C, Camci C: Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol; 2009 Feb;63(3):555-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.
  • The majority of uterine sarcomas are leiomyosarcoma and endometrial stromal sarcoma (ESS).
  • Surgery, radiotherapy, chemotherapy, and hormonal therapy are used for the treatment of ESS.
  • Imatinib mesylate is indicated in the management of gastrointestinal stromal tumor and chronic myelogeneus leukemia.
  • There is an interest to use imatinib mesylate in the treatment of c-kit positive ESS.
  • We reported a case of 42-year-old female low-grade ESS progressed on chemotherapy and presented with objective response to imatinib mesylate.
  • The treatment response was evaluated with FDG PET/CT.
  • FDG PET, a sensitive method for tumor response evaluation on the basis of tumor metabolism changes, is useful for the evaluation of imatinib treatment in low-grade ESS.
  • [MeSH-major] Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Chemother Pharmacol. 2009 Feb;63(3):561
  • (PMID = 18607592.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


11. Alkasi O, Meinhold-Heerlein I, Zaki R, Fasching P, Maass N, Jonat W, Beckmann MW: Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report. Arch Gynecol Obstet; 2009 Jan;279(1):57-60
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
  • BACKGROUND: Approximately 50% of patients with low-grade endometrial stromal sarcoma (ESS) develop recurrent disease including mainly metastases of pelvis and lung.
  • CASE: After initial surgical treatment in 1990, a 28-year-old female developed solitary metastases of the lung in 1998 and 1999, which were surgically removed both times.
  • CONCLUSIONS: This case report emphasizes the importance of long-term follow-up and initial surgical treatment of low-grade ESS and suggests systemic hormonal therapy in case of recurrence.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Female. Goserelin / therapeutic use. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Nitriles / therapeutic use. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379806.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 0F65R8P09N / Goserelin; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


12. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS: Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1084-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases.
  • The aim of this retrospective study was to evaluate the clinical behavior and management outcome of low-grade endometrial stromal sarcoma (LGESS).
  • Six patients had adjuvant therapy after the hysterectomy.
  • Recurrent disease was treated with surgery (one case), surgery plus chemotherapy (five cases), chemotherapy (two cases), and surgery plus radiotherapy (two cases).
  • Treatment with a bilateral salpingo-oophorectomy or adjuvant chemoradiation did not affect the disease-free interval.
  • Surgery is the primary treatment for recurrent endometrial stromal sarcoma when feasible.
  • Adjuvant treatment (radiotherapy, chemotherapy, or both) had no effect on the prognosis of patients with stage I disease.
  • [MeSH-major] Sarcoma, Endometrial Stromal / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179547.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yokoyama Y, Ono Y, Sakamoto T, Fukuda I, Mizunuma H: Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection. Gynecol Oncol; 2004 Mar;92(3):999-1001
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection.
  • BACKGROUND: The endometrial stromal sarcoma (ESS) is a rare neoplasm of the uterine origin.
  • Intracardiac metastasis from the low-grade ESS is an extremely rare event.
  • A case of a patient who successfully underwent surgical extraction of metastatic tumors of the low-grade ESS in the right ventricle is described in the present report.
  • CASE: A 48-year-old woman was considered recurrence of the low-grade ESS 4 years after the initial operation for this disease.
  • The chemotherapy was effective against the recurrent tumors except for intracardiac site.
  • Pathological examination confirmed intracardiac recurrent low-grade ESS.
  • CONCLUSION: Surgical approach to intracardiac metastasis of the low-grade ESS is considered viable because of an excellent long-term prognosis in this disease and the likelihood of fatal heart failure or sudden death in untreated cases.
  • [MeSH-major] Endometrial Neoplasms / pathology. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Sarcoma, Endometrial Stromal / secondary. Sarcoma, Endometrial Stromal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984976.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lim MC, Lee S, Seo SS: Megestrol acetate therapy for advanced low-grade endometrial stromal sarcoma. Onkologie; 2010;33(5):260-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megestrol acetate therapy for advanced low-grade endometrial stromal sarcoma.
  • BACKGROUND: Pulmonary metastases as an initial presentation of primary uterine low-grade endometrial stromal sarcoma (LGESS) are extremely rare.
  • Optimal treatment for such LGESS has not been established.
  • Chest computed tomography (CT) revealed 11 pulmonary metastases measuring up to 2.8 cm.
  • The pulmonary metastases of LGESS began to regress with megestrol acetate treatment and almost completely disappeared 17 months after surgery.
  • At this unexpected and satisfactory response to hormonal treatment, the remaining left ovary was also surgically removed.
  • Since the surgery, the patient has been alive without symptomatic pulmonary metastases over 5 years on intermittent treatment of 200 mg megestrol acetate.
  • CONCLUSION: Megestrol acetate could be suitable as the first-line hormonal treatment for pulmonary metastases from LGESS.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Megestrol Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / secondary
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Fallopian Tubes / surgery. Female. Humans. Neoplasm Staging. Omentum / surgery. Ovariectomy. Palliative Care

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20502061.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


15. Reich O, Regauer S: Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol; 2007 Jul;19(4):347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy of endometrial stromal sarcoma.
  • PURPOSE OF REVIEW: Low-grade endometrial stromal sarcomas are steroid receptor positive tumors with slow tumor progression and high recurrence rates, which lack established treatment protocols.
  • We present an update on hormonal therapy options.
  • RECENT FINDINGS: In the past, hormonal therapy consisted of progestins for advanced/recurrent/metastatic low-grade endometrial stromal sarcomas.
  • Aromatase inhibitors and gonadotropin-releasing hormone analogues have become new effective alternatives for first and second line treatment.
  • The high recurrence rates after short disease free intervals in low-grade endometrial stromal sarcoma patients were partly due to inadvertent growth stimulation during estrogen-containing hormone replacement therapy and tamoxifen treatment, which - according to current knowledge - are contraindicated.
  • Recently, hormonal therapy has been introduced for the prevention of recurrences.
  • Aromatase inhibitors are becoming the treatment of choice, since progestins are poorly tolerated due to side effects.
  • The effective duration of preventive hormonal therapy is still undetermined.
  • SUMMARY: Hormonal therapy with progestins, aromatase inhibitors and gonadotropin-releasing hormone analogues has become an effective treatment alternative to radiation and chemotherapy for low-grade endometrial stromal sarcoma patients.
  • Preventive hormonal therapy is of particular interest in the setting of concomitant endometriosis.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Aromatase Inhibitors / therapeutic use. Female. Goserelin. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545798.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 50
  •  go-up   go-down


16. Garavaglia E, Pella F, Montoli S, Voci C, Taccagni G, Mangili G: Treatment of recurrent or metastatic low-grade endometrial stromal sarcoma: three case reports. Int J Gynecol Cancer; 2010 Oct;20(7):1197-200
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent or metastatic low-grade endometrial stromal sarcoma: three case reports.
  • BACKGROUND: The treatment of recurrent or metastatic low-grade endometrial stromal sarcoma (LG-ESS) is still controversial.
  • Responses to hormonal therapy have been reported, because of the presence of estrogen and progestin receptors.
  • Also chemotherapy has been used, but the percentage of response is low.
  • The second patient developed pelvic and abdominal recurrences, managed by surgery, 33 months after primary treatment and a subsequent lung recurrence 11 years later.
  • CONCLUSIONS: In LG-ESS, the combined treatment of surgery and progestin therapy is effective in achieving both local and distant disease control.
  • Metastatic lesions, especially pulmonary lesions, seem to benefit from surgical removal, followed by progestin therapy.
  • Hormonal therapy should be maintained for an indefinite period.
  • On account of the long period existing between primary tumor and recurrent disease, a long-term follow-up is always recommended after the primary treatment.
  • [MeSH-major] Endometrial Neoplasms / surgery. Endometrial Stromal Tumors / surgery. Hysterectomy. Neoplasm Recurrence, Local / surgery. Sarcoma, Endometrial Stromal / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495227.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C: Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol; 2001 Aug;82(2):384-8
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial stromal sarcoma: objective response to letrozole.
  • BACKGROUND: Low-grade endometrial stromal sarcoma is generally an indolent tumor rich in estrogen and progesterone receptors.
  • Objective responses to hormonal therapy, most commonly with megestrol acetate, have been reported.
  • CASE: The patient is a 51-year-old woman who presented with low-grade endometrial stromal sarcoma confined to the uterus in 1991 and was treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy.
  • Approximately 5 years later, the patient had recurrent pelvic disease treated with radiation therapy, followed by an attempt at resection.
  • She was treated with megestrol acetate during the period she received radiation therapy with poor tolerance.
  • CONCLUSION: Letrozole at a daily dose of 2.5 mg may be effective in low-grade endometrial stromal sarcoma with positive estrogen receptors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11531300.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


18. Liao JB, Lin JY: Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy. Eur J Gynaecol Oncol; 2001;22(6):417-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy.
  • INTRODUCTION: Several cases of low-grade endometrial stromal sarcomas in women with breast cancer have been reported to be associated with tamoxifen therapy.
  • Estrogen receptor expression has been used to characterize the partial estrogenic action of tamoxifen on the endometrium and has been found in tamoxifen-associated endometrial pathologies.
  • CASE: A low-grade endometrial stromal sarcoma in a woman with a history of breast cancer treated with adjuvant tamoxifen is presented.
  • CONCLUSION: The absence of estrogen receptor expression suggests that endometrial stromal sarcomas are not necessarily caused by the estrogenic properties of tamoxifen.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Estrogen Antagonists / therapeutic use. Receptors, Estrogen / analysis. Sarcoma / drug therapy. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874071.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


19. Burke C, Hickey K: Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol; 2004 Nov;104(5 Pt 2):1182-4
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue.
  • BACKGROUND: Endometrial stromal sarcoma can present management difficulties due to its lack of response to conventional chemotherapy and radiotherapy.
  • Various hormonal therapies have been shown to reduce tumor volume in both primary and recurrent disease.
  • CASE: A woman who underwent myomectomy was discovered to have a low-grade endometrial stromal sarcoma.
  • Treatment with the gonadotropin-releasing hormone (GnRH) analogue triptorelin before surgery had produced reduction in uterine size.
  • The woman developed tumor recurrence six months after definitive surgical treatment.
  • Biopsy results confirmed recurrent low-grade endometrial stromal sarcoma with moderate estrogen and progesterone receptor positivity.
  • CONCLUSION: Control of progression of a recurrent endometrial stromal sarcoma was achieved with the GnRH analogue triptorelin.
  • This is the first report in the English-language literature during a 30-year period of single-agent GnRH analogue being an effective treatment intervention in this context.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / pathology. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Intraoperative Care / methods. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516445.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


20. Dahhan T, Fons G, Buist MR, Ten Kate FJ, van der Velden J: The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol; 2009 May;144(1):80-4
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.
  • OBJECTIVE: Low-grade endometrial stromal sarcoma (EES) is a rare tumour with a high recurrence rate but a very good prognosis.
  • Responses to hormonal treatment of these recurrences have been published in case reports.
  • The aim of this study was to determine the objective response rate and response duration of hormonal treatment for recurrent or residual low-grade ESS in a consecutive series of patients.
  • The following data were collected: age, date of primary diagnosis, type of primary treatment, the presence and localization of residual or recurrent disease, type of treatment, response, duration of response and survival.
  • RESULTS: After hormonal treatment 9 (82%) patients showed an objective response (4 complete response; 5 partial response), one showed stable disease (26+ months) and one progressive disease.
  • CONCLUSION: Hormonal treatment for measurable residual or recurrent low-grade ESS has a high response rate and should be considered as the treatment of choice for patients in which recurrent disease cannot easily be resected.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Megestrol Acetate / therapeutic use. Nitriles / therapeutic use. Progestins / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Aged, 80 and over. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Secondary Prevention. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269732.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Progestins; 0 / Triazoles; 7LKK855W8I / letrozole; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


21. Gadducci A, Cosio S, Genazzani AR: Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs; 2004 Oct;5(10):1031-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new anti-estrogens, including the selective estrogen receptor modulators (e.g., toremifene, droloxifene, idoxifene, raloxifene and arzoxifene), the selective estrogen receptor downregulators (e.g., fulvestrant), and the new steroidal (e.g., exemestane) and non-steroidal (anastrozole and letrozole) aromatase inhibitors have been investigated in the treatment of breast cancer and hormonally sensitive tumors of the uterine body.
  • In postmenopausal women, anastrozole, letrozole and exemestane appear to have superior efficacy and an improved toxicity profile than tamoxifen, and fulvestrant seems to be at least as effective as anastrozole in patients in whom tumors have progressed after prior endocrine treatment.
  • Preliminary data showed a high response rate and a favorable toxicity profile for arzoxifene in endometrial cancer, whereas letrozole could represent a new interesting therapeutic tool for endometrial cancer as well as for low-grade endometrial stromal sarcoma.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Estrogen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Clinical Trials as Topic. Female. Humans

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15535424.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Estrogen Antagonists
  • [Number-of-references] 161
  •  go-up   go-down


22. Bosincu L, Massarelli G, Cossu Rocca P, Isaac MA, Nogales FF: Rectal endometrial stromal sarcoma arising in endometriosis: report of a case. Dis Colon Rectum; 2001 Jun;44(6):890-2
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal endometrial stromal sarcoma arising in endometriosis: report of a case.
  • PURPOSE: Endometriosis of the rectovaginal septum can harbor different types of secondary tumors that may involve the rectal wall and protrude into its lumen, thus making diagnosis difficult.
  • Extrauterine low-grade endometrial stromal sarcoma may rarely arise in endometriosis.
  • Histopathologically, primary endometriotic foci were found in close relationship with an endometrial stromal sarcoma which invaded the rectal wall.
  • The patient was treated by surgery and subsequent chemotherapy and was alive and well 20 months later.
  • CONCLUSIONS: Endometriosis and its possible malignant changes should be taken into account in the differential endoscopic diagnosis of rectal masses in females.
  • [MeSH-major] Endometrial Neoplasms / etiology. Endometriosis / complications. Sarcoma / etiology
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Female. Fever / etiology. Humans. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11391154.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Gadducci A, Cosio S, Romanini A, Genazzani AR: The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol; 2008 Feb;65(2):129-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of patients with uterine sarcoma: a debated clinical challenge.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the standard surgical treatment.
  • Pelvic and/or para-aortic lymphadenectomy is indicated for carcinosarcoma, but not for leiomyosarcoma and undifferentiated endometrial sarcoma.
  • Some recent data on low numbers of patients with low-grade endometrial stromal sarcoma appear to show an incidence of nodal involvement higher than previously expected, thus suggesting a role for lymphadenectomy in this malignancy.
  • Postoperative treatment of uterine sarcomas has been long debated.
  • There is little evidence in the literature supporting the use of adjuvant chemotherapy in any gynaecological sarcomas except for carcinosarcomas.
  • However, uterine sarcomas have a high tendency to develop distant recurrences, and recent data on adjuvant chemotherapy in soft tissue sarcomas are promising.
  • As for the drugs to be used, it is worth noting that in a Swiss study, the combination of ifosfamide (IFO) and doxorubicin (DOX) obtained similar response rates in advanced gynaecological sarcomas and in advanced soft tissue sarcomas of other sites.
  • In our decision-making scheme for early-stage disease, patients with leiomyosarcoma or undifferentiated endometrial sarcoma should receive adjuvant doxorubicin/epidoxorubicin (EPIDX)+ifosfamide, and those with carcinosarcoma should be treated with adjuvant cisplatin (CDDP)-based chemotherapy.
  • The same drug regimens are used for the treatment of advanced disease.
  • Sequential pelvic radiotherapy following chemotherapy could be delivered to selected cases.
  • Recurrent disease often requires the integration of different therapeutic modalities, but no curative option is currently available with the possible exception of surgery for lung metastases and hormone therapy with or without debulking surgery for recurrent low-grade endometrial stromal sarcoma.
  • Patients should be encouraged to enter clinical trials designed to identify new active drugs for these malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706430.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 177
  •  go-up   go-down


24. Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, Reichardt P: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol; 2006 Jun;101(3):464-9
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
  • Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the US or EU per year.
  • A higher risk in women receiving estrogen replacement therapy (ERT) or tamoxifen has been suspected, and remissions following treatment with progestins have been reported in case studies.
  • Aromatase inhibitors represent an interesting new treatment option.
  • We therefore conducted a retrospective study to evaluate the influence of hormonal treatment to ESS.
  • METHODS: Our institutional sarcoma data bank was screened for cases of ESS since 1999.
  • RESULTS: Ten patients with low-grade ESS were identified.
  • 5/10 patients were on ERT and 3/10 on tamoxifen at the time of diagnosis of metastatic disease.
  • Treatment strategies consisted of stopping ERT and tamoxifen, respectively, or initiation of the progestin MPA or letrozole.
  • 2/3 patients responded to MPA as first-line treatment (1 CR; 50+ months, 1 PR; 9 months).
  • 4/5 patients responded to letrozole as first-line therapy (3 PR;3+, 9+ and 10+ months) or second-line treatment after MPA (1 PR; 37+ months).
  • CONCLUSIONS: Patients with a previous history of low-grade ESS should not be treated with estrogens or tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Stromal Tumors / drug therapy. Estrogen Replacement Therapy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Medroxyprogesterone Acetate / adverse effects. Medroxyprogesterone Acetate / therapeutic use. Middle Aged. Nitriles / adverse effects. Nitriles / therapeutic use. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Retrospective Studies. Tamoxifen / adverse effects. Tamoxifen / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use. Uterine Neoplasms / drug therapy. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2006 Aug;102(2):413-4; author reply 414 [16712906.001]
  • (PMID = 16368128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


25. Bréchot JM, Kamboucher M, Brauner M, Destable MD, Duperron F, Morère JF: [Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]. Rev Mal Respir; 2007 Jan;24(1):69-72
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy].
  • [Transliterated title] Les métastases pulmonaires de sarcomes utérins peuvent bénéficier d'une hormonothérapie!
  • INTRODUCTION: Low grade endometrial stromal sarcoma (ESS) often expresses oestrogen (ER) and progesterone (PR) receptors, even in metastatic disease.
  • CASE REPORT: Two years after the institution of oestrogen replacement therapy (HRT) a woman of 56 presented with haemoptysis which led to the discovery of multiple pulmonary nodules.
  • Twelve years previously the patient had had a hysterectomy for a low grade endometrial stromal sarcoma, ER and PR positive.
  • Surgical resection of the nodules on the right side confirmed the diagnosis of metastatic endometrial stromal sarcoma.
  • Three months after the withdrawal of HRT and treatment with an aromatase inhibitor (letrozole) the contralateral metastases had disappeared and this complete response was maintained for more than 2 years of follow-up.
  • CONCLUSION: Care should be taken in the institution of HRT in a woman with a history of low grade ESS.
  • Hormonal treatment with aromatase inhibitors may be considered in cases where ER and PR are expressed by the primary tumour and metastases, with possible benefits even in metastatic disease.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / secondary. Triazoles / therapeutic use. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268368.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


26. Tzakas E, Liu S, Todd RW, Redman CW: Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS). J Obstet Gynaecol; 2009 Nov;29(8):778-9
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821687.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down






Advertisement